logo
What Boston Celtics president Brad Stevens said about the team's future

What Boston Celtics president Brad Stevens said about the team's future

USA Today19-05-2025
What Boston Celtics president Brad Stevens said about the team's future
Whatever the Boston Celtics are going to do this offseason, they are not ready to talk to the media about it. Celtics President of Basketball Operations Brad Stevens sat down with the media this afternoon for the first time since Boston was eliminated by the New York Knicks in their 2025 NBA Eastern Conference Semifinals second round series that ended in six games, and Stevens was exceptionally tight-lipped about the team's future plans.
He did hint that there may be more to say closer to the 2025 NBA draft, which is in itself a statement that the Celtics may have some moves in mind they are not ready to discuss or even encourage speculation on. But in an availability that lasted nearly a half-hour, the team president said remarkably little about Boston's future in any detail.
Let's take a look at a what Stevens did have to say about what the offseason may hold for Boston
On discussing the future more generally
Here, the Celtics president was most opaque, sharing what he would not share as much as he was letting anything concrete slip. "We'll talk about all that stuff in the next few weeks," said Stevens, trying to shut down forward-facing lines of inquiry from the media before it built up any inertia.
"We've been talking about this for years," he added, specifically touching on team financials and what might be coming as a result of their projected historic payroll and tax bill. "The (collective bargaining agreement) has been well known for years, and so there are penalties associated with being at certain levels, and we know that."
"You just weight that, where we are, you weigh everything else, and then you make those decisions. You have to have the full clarity of a full season, a full playoffs, and ... a couple good nights sleep, and everybody gets in the room and puts their heads together and figures out what's next."
On Jaylen Brown's knee
It was recently revealed that Brown has been playing on a partially torn meniscus for a fair amount of the 2024-25 NBA regular season, as well as all of the postseason. While it elevated the impact of what the Georgia native was able to accomplish, it also raised a number of additional questions, none of which were answered by Stevens.
The Celtics president did give some additional context on the situation, however, noting Brown has been playing with the injury for a while now. "Jaylen wants to play. Jaylen's a competitor. Jaylen's a warrior," he explained. "Jaylen takes great pride in being out there. "At the same time, he saw our team (doctors), and a couple of other people and and as he even said a couple of weeks ago that the knee's in a good place structurally."
"I think he felt comfortable getting out there and going after it, and hopefully he'll feel better after being off of it for a couple of weeks. The unfortunate part is we're done in the middle of May."
Regarding Jayson Tatum's Achilles injury
"Obviously, it's going to be a longer span of time with Jayson here," offered Stevens when asked about the stability Brown might provide with Tatum likely out for much or all of the coming season. "(Tatum and Brown) have been the core parts of this whole program for a while. There's no question about that -- those guys have achieved so much, and certainly deserve all the recognition and praise and accolades they get. That's a huge part of us being the best versions of ourselves."
As for the impact of Tatum's injury on summer plans, Stevens was equally hard to pin down. "I think anytime you're talking about an injury like that, I think it's another piece of information that you have to ingest and and figure out how that affects you moving forward, both next year and in the future," he suggested cryptically.
Noting that Tatum has a long rehab ahead, he pointed out the minor silver lining of the injury happening almost on the doorstep of one of the best doctors in the world who specializes in them. "There was a real benefit to doing it early," he explained.
On Kristaps Porzingis' lingering illness
"I don't think anybody was more frustrated than him," said Stevens. "I felt for him. The way it was described to me was just postviral syndrome, which is just lingering effects of a long illness.
"I think we've we've seen that and probably all read too much about that over the last several years," he added. "But I think that unfortunately I thought he had really turned the corner there towards the end of the regular season." For whatever reason, that was not the case consistently through the postseason for KP. Noting that the postseason grind is far from an ideal environment for recovery, the Boston president said "the next couple of weeks will do him good to be off," even though he plans to play for Latvia in international play.
On how the approach to the draft might change
"I don't think it changes at all for us," Stevens said when asked if Boston's approach to the 2025 NBA draft could shift given all the above. "We'll evaluate who we think will be available at (pick Nos.) 28 and 32. We just got done with two draft workouts today. We have plenty of time to thoroughly evaluate who we think those people might be.
"If we want to try to move up, try to move back, you know, whatever -- we'll see how it all goes. I think when you're at 28 and 32, you're not exactly able to pinpoint exactly how that night's going to go."
Regarding Joe Mazzulla as coach
"Joe's great. Joe's done a great job," shared Stevens, addressing a question about the recent trends of coach firings and what he thought of Mazzulla in such a light. "I don't think anyone in coaching ever thought it was certain. I think uncertainty is what you sign up for in some ways."
"But listen, here's so many things that go into winning and losing, and coaching's part of it, right?" the Celtics president related rhetorically.
"But playing circumstances, injuries, whatever the case may be, there's so many things ... I know how hard their jobs are, and I've felt for Taylor (Jenkins) and for Mike (Malone) ... They're way better than everybody thinks or knows. That's the reality of our situation because that's the way the world works and and there are other coaches that are really good too, that'll get their opportunities."
"But we're lucky that we have Joe here," he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Xoma strikes deals to buy struggling biotechs HilleVax, Lava
Xoma strikes deals to buy struggling biotechs HilleVax, Lava

Yahoo

time35 minutes ago

  • Yahoo

Xoma strikes deals to buy struggling biotechs HilleVax, Lava

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Xoma Royalty Corporation on Monday announced a pair of agreements to acquire biotechnology companies HilleVax and Lava Therapeutics, which have both struggled since going public several years ago. Xoma offered $1.95 per HilleVax share to investors in that company, as well as rights to any additional cash HilleVax holds above roughly $103 million at deal closing, a portion of any savings on a Boston building lease and 90% of any proceeds from the sale of HilleVax's norovirus vaccine programs. HilleVax went public in 2022 with plans to develop a vaccine for moderate or severe acute gastroenteritis. Co-founded by Tadataka Yamada, a former Takeda Pharmaceutical executive, and Frazier Life Sciences, it raked in $200 million to progress a vaccine it had licensed from the Japanese pharmaceutical company. HilleVax's value has plummeted over the past two years, however, after a mid-stage trial showed its vaccine was ineffective, causing the company to halt development of its lead program in infants, cut 40% of its staff and seek strategic alternatives. For Lava, Xoma is paying at least $1.16 — and potentially up to $0.08 more — per share of the Dutch company. It is also offering a contingent value right worth 75% of net proceeds from its partnered programs and any sale of its wholly owned pipeline assets. 'We believe the structure of this transaction has the potential to benefit both Lava and Xoma Royalty shareholders over time,' Xoma CEO Owen Hughes said in a statement on the Lava deal. Lava makes a type of bispecific antibody for cancer called gamma delta T cell engagers. It has a pair of programs in development with Pfizer and Johnson & Johnson, the former of which is for solid tumors while the latter is focused on blood cancers. The Netherlands-based biotech previously licensed out a preclinical prospect to Seagen. In February, the company announced it would lay off 30% of its staff after disappointing results from a study of its lead program. Lava CEO Steve Hurly said at the time that, 'with only one product in clinical development and an early-stage pipeline,' it was 'appropriate to investigate strategic opportunities.' Both HilleVax and Lava are examples of 'biotech zombies' — companies that, due to research or other setbacks, trade at market capitalizations below their cash holdings. In recent quarters, these companies have come under pressure to dissolve and return that cash to shareholders, while others have chosen reverse mergers or buyout deals like the two struck by Xoma Monday. Concentra Biosciences has emerged as a major player in the acquisition of these distressed biotechs, striking several deals this year to buy Cargo Therapeutics, Elevation Oncology and Allakos. Other firms are taking note. Last week, KKR said it acquired a majority ownership stake in HealthCare Royalty Partners, which has pursued a similar business model to Xoma. And earlier this year, Alis Biosciences launched with a new fund with the goal of freeing 'trapped' capital on balance sheets in biotech. Venture investors are working on ways to support struggling startups, too. On Monday, OrbiMed, a prolific equity funder of new biotechs, announced a $1.86 billion fund for 'non-dilutive credit and royalty-based financing.' Recommended Reading Replay reveals second gene therapy spinout, debuting new biotech Telaria Connectez-vous pour accéder à votre portefeuille

NBA analyst projects nightmare season for Celtics after offseason moves
NBA analyst projects nightmare season for Celtics after offseason moves

Yahoo

time3 hours ago

  • Yahoo

NBA analyst projects nightmare season for Celtics after offseason moves

NBA analyst projects nightmare season for Celtics after offseason moves originally appeared on The Sporting News The Boston Celtics have made some wild moves this offseason, and it might lead to a rough season. Over the past couple of months, the Celtics have steadily torn down their championship core. With Brad Stevens running the show, he has made some of the biggest moves of the offseason to help the Celtics gain some more financial flexibility after the team was in danger of hitting the second apron. With most of the offseason moves already taken care of, the Celtics don't have much more they can do before the start of next season. With Jrue Holiday and Kristaps Porzingis among the players who are on new teams, the Celtics could take a step back next season, especially with Jayson Tatum set to miss the entire season. While Boston's sights are still set on the playoffs, John Schuhmann projects a much darker year for the Celtics. In his power ranking of teams in the East, Schuhmann placed the Celtics at No. 12, ahead of only the Charlotte Hornets, Washington Wizards and Brooklyn Nets. In other words, the Celtics are in company with the worst in basketball. While Boston might not be able to contend for a title next season, projecting it as a team that might miss the postseason entirely is a bit shocking, but it certainly has some legs. With the middle of the East getting better and the Celtics having a massive dropoff in talent, the possibility of them missing the play-in is legitimate, and they might have their worst season in over a decade.

OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference
OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference

Yahoo

time3 hours ago

  • Yahoo

OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference

WARSAW, Ind., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ('OrthoPediatrics' or the 'Company') (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 45th Canaccord Genuity Annual Growth Conference, held in Boston, MA. Event: 45th Canaccord Genuity Annual Growth Conference Format: Fireside ChatDate: Wednesday, August 13, 2025Time: 11:00 am ET An audio webcast of the discussion will be available online at the OrthoPediatrics' investor relations website, Additionally, a replay will be available after the event. About OrthoPediatrics in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit Investor Contact Philip Trip Taylor Gilmartin Groupphilip@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store